Larry S. Dean, MD, provides insight on the randomized SURTAVI trial, which was presented in a late-breaking session at the ACC scientific session. At two years, intermediate-risk patients with severe symptomatic aortic stenosis had similar rates of all-cause mortality or disabling stroke whether they underwent TAVR or SAVR. Dean says the results confirm findings from the PARTNER IIA trial, which showed that TAVR can be effective in lower risk patients.